70 related articles for article (PubMed ID: 21923591)
1. Liraglutide and Robust A1C Reductions Among People With Type 2 Diabetes Requiring Appetite Control: A Review of Two Cases.
Pitts MA; Griggs RH; Hall MR; Tankersley MS; Johnson JL
Diabetes Spectr; 2024; 37(2):175-179. PubMed ID: 38756434
[No Abstract] [Full Text] [Related]
2. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
Alves C; Batel-Marques F; Macedo AF
Diabetes Res Clin Pract; 2012 Nov; 98(2):271-84. PubMed ID: 23010561
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
Owens DR; Monnier L; Bolli GB
Diabetes Metab; 2013 Dec; 39(6):485-96. PubMed ID: 24156868
[TBL] [Abstract][Full Text] [Related]
4. GLP-1R agonist therapy for diabetes: benefits and potential risks.
Samson SL; Garber A
Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):87-97. PubMed ID: 23403741
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory benefits of semaglutide: State of the art.
Yaribeygi H; Maleki M; Jamialahmadi T; Sahebkar A
J Clin Transl Endocrinol; 2024 Jun; 36():100340. PubMed ID: 38576822
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effect of engineered
Wang Y; Chen WJ; Han YY; Xu X; Yang AX; Wei J; Hong DJ; Fang X; Chen TT
Bioeng Transl Med; 2023 May; 8(3):e10505. PubMed ID: 37206220
[TBL] [Abstract][Full Text] [Related]
7. Effect of liraglutide on atherosclerosis in patients with impaired glucose tolerance: A double‑blind, randomized controlled clinical trial.
Sun L; Yuan Y; Li Y; Rao X
Exp Ther Med; 2023 Jun; 25(6):249. PubMed ID: 37153886
[TBL] [Abstract][Full Text] [Related]
8. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.
Gallwitz B
Front Endocrinol (Lausanne); 2022; 13():1004044. PubMed ID: 36313764
[TBL] [Abstract][Full Text] [Related]
9. Relevance of AIF/CypA Lethal Pathway in SH-SY5Y Cells Treated with Staurosporine.
Conte M; Palumbo R; Monti A; Fontana E; Nebbioso A; Ruvo M; Altucci L; Doti N
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008690
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effects of liraglutide against inflammation through the AMPK/NF-κB pathway in a mouse model of Parkinson's disease.
Cao B; Zhang Y; Chen J; Wu P; Dong Y; Wang Y
Metab Brain Dis; 2022 Feb; 37(2):451-462. PubMed ID: 34817756
[TBL] [Abstract][Full Text] [Related]
11. DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment.
Mikov M; Pavlović N; Stanimirov B; Đanić M; Goločorbin-Kon S; Stankov K; Al-Salami H
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):1-14. PubMed ID: 31385198
[TBL] [Abstract][Full Text] [Related]
12. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus.
Tangvarasittichai S
World J Diabetes; 2015 Apr; 6(3):456-80. PubMed ID: 25897356
[TBL] [Abstract][Full Text] [Related]
13. An accidental liraglutide overdose: case report.
Elmehdawi RR; Elbarsha AM
Libyan J Med; 2014; 9(1):23055. PubMed ID: 24461534
[No Abstract] [Full Text] [Related]
14. The future role of gut hormones in the treatment of obesity.
Troke RC; Tan TM; Bloom SR
Ther Adv Chronic Dis; 2014 Jan; 5(1):4-14. PubMed ID: 24381724
[TBL] [Abstract][Full Text] [Related]
15. Liraglutide suppresses the plasma levels of active and des-acyl ghrelin independently of active glucagon-like Peptide-1 levels in mice.
Nonogaki K; Suzuki M
ISRN Endocrinol; 2013; 2013():184753. PubMed ID: 23997963
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study.
Idorn T; Knop FK; Jørgensen M; Jensen T; Resuli M; Hansen PM; Christensen KB; Holst JJ; Hornum M; Feldt-Rasmussen B
BMJ Open; 2013; 3(4):. PubMed ID: 23624993
[TBL] [Abstract][Full Text] [Related]
17. Liraglutide: clinical pharmacology and considerations for therapy.
Sisson EM
Pharmacotherapy; 2011 Sep; 31(9):896-911. PubMed ID: 21923591
[TBL] [Abstract][Full Text] [Related]
18. Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
Bode B
Am J Manag Care; 2011 Mar; 17(2 Suppl):S59-70. PubMed ID: 21517658
[TBL] [Abstract][Full Text] [Related]
19. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
